MedTrace Logo

Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

NCT03617666 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-12-12

No results posted yet for this study

Summary

This is a phase II, non-randomised, multicentre study to assess the safety and efficacy of the PD-L1 inhibitor, avelumab, in a previously untreated fit population of high risk stage II, stage III and stage IV classical Hodgkin lymphoma.

Conditions

Interventions

DRUG

Avelumab

Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University College, London

    lead OTHER

Principal Investigators

  • Graham Collins · Churchill Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2022-07-04
Completion
2025-05-30

Countries

  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03617666 on ClinicalTrials.gov